Revive Therapeutics Provides Update From FDA Meeting for Long COVID Diagnostic Product

[Mij]

“We agree with the FDA feedback and with their recommendations that provides a pathway for the development of the Revive LC POC Lateral Flow Test Kit in the detection of long COVID,” said Michael Frank, CEO of Revive. “We will now discuss the proposed development plan and timelines with potential contract manufacturers.”

Currently, there is no FDA-approved clinical diagnosis of long COVID and it is estimated to occur in at least 10% of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections. More than 200 symptoms have been identified with impacts on multiple organ systems — including fatigue, brain fog, difficulty breathing, and cardiovascular symptoms ranging from chest pain and arrhythmias to sudden cardiac death—but it remains a diagnosis of exclusion with an unknown biological basis.

LINK

 

[Mij]

Scientific Rationale for the Investigation of Bucillamine to Treat Infectious Diseases, including COVID-19

Rivive Therapeutics

 

[forestglip]

The Company, under its wholly-owned subsidiary Revive Diagnostics Inc., is advancing the Product as a potential blood biomarker diagnostic that characterizes long COVID. The discovery of the biomarkers identified by a research team at Lawson, led by Dr. Douglas Fraser, was recently published in the journal, Molecular Medicine1.

So it seems the test will be based on this paper:

Elevated vascular transformation blood biomarkers in Long-COVID indicate angiogenesis as a key pathophysiological mechanism 2022, Patel et al

 

[EndME]

The story I've seen is that Douglas Fraser who has published a lot of similar papers on Long-Covid (see references 1,2,3,4,5) first sold the rights to his "test" to QMC Health (see https://www.globenewswire.com/en/ne...f-High-Sensitivity-Long-COVID-Rapid-Test.html). That seems to have never lead anywhere.

Now it seems Revive Diagnostics Inc have picked it up. Neither of those companies inspire too much confidence in me.

The problem remains that those above papers haven't inspired too much confidence in the past few years, given the cohorts chosen and that no one has really been able to replicate much of it.